ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Financial Statements
Our financial statements and notes thereto appear on pages F-1 through F-21
in this Form 10-K.
Selected Quarterly Financial Data unaudited                           YEAR ENDED DECEMBER 31, 1999        YEAR ENDED DECEMBER 31, 2000
FIRST 1  SECOND1  THIRD1
FIRST   SECOND   THIRD    FOURTH  RESTATED RESTATED RESTATED  FOURTH
IN THOUSANDS, EXCEPT PER SHARE DATA
Total revenues.. $ 15,531  $ 2,944  $ 1,363  $ 2,394  $ 3,407  $ 3,128  $ 3,619  $ 22,089
Net loss, before cumulative
effect of change in accounting
principle..  1,519  15,120  22,618  22,613  29,025  18,125  18,786  11,574
Cumulative effect of change in
accounting principle..    --     --     --     --  12,750     --     --                                           Net loss, after cumulative effect
of change in accounting principle.. $ 1,519 $15,120  $22,618  $22,613 $41,775  $18,125  $18,786 $11,574
Basic and diluted net loss per
share:
Net loss, before cumulative
effect of change in accounting
principle.. $ 010 $ 096  $ 143  $ 140 $ 170  $ 086  $ 087 $ 050
Cumulative effect of change in
accounting principle..    --     --     --     --   074     --     --                                            Net loss, after cumulative effect
of change in accounting principle.. $ 010 $ 096  $ 143  $ 140 $ 244  $ 086  $ 087 $ 050
Shares used in computing basic and
diluted net loss per share..  15,703   15,749   15,814   16,126   17,095   21,039   21,625   23,100
1 Total revenues, net loss and net loss per share have been restated as
compared to our previously reported results, as a result of the adoption of
SAB 101, effective January 1, 2000. The impact of the restatement was as
follows                         YEAR ENDED DECEMBER 31, 2000
FIRST    SECOND   THIRD
IN THOUSANDS, EXCEPT
PER SHARE DATA
Increase in total revenue.. $  750    $ 750   $ 750
Decrease increase in net loss.. $12,000   $ 750   $ 750
Decrease increase in net loss per share.. $ 070   $ 004   $003
Item 1.   3
Item 2.   30
Item 3. Legal  31
Item 4. Submission of Matters to a Vote of Security  31
PART  32
Item 5. Market for the Registrant Common Stock and Related Stock  32
Item 6. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
The information regarding directors required by this item will be contained
in our definitive Proxy Statement with respect to our Annual Meeting of
Stockholders to be held on June 14, 2001, under the captions Election of
Directors -- Nominees, and Security Ownership of Certain Beneficial Owners and
Management -- Compliance with the Reporting Requirement of Section 16a, and
is incorporated by reference.
EXECUTIVE OFFICERS
The names of our executive officers as of March 22, 2001 and information
about them is presented below.    NAME               AGE                 POSITION
EXECUTIVE OFFICERS
C. Boyd Clarke. 52  Chief Executive Officer, President and Chairman
Edward J. Arcuri, Ph.D. 50  Senior Vice President, Operations
Charlene A. Friedman. 43  Vice President, General Counsel and Secretary
Harry B. Greenberg, M.D. 56  Senior Vice President, Research and Development and Chief Scientific Officer
Fred Kurland. 51  Senior Vice President and Chief Financial Officer
Carol A. Olson. 43  Senior Vice President, Commercial Development
Rayasam S. Prasad. 48  Senior Vice President, Technical Affairs   C. Boyd Clarke has been our President and Chief Executive Officer since
December 1999. He has been a director since December 1999 and our Chairman since
January 2001. From 1998 until joining us, Mr. Clarke was Chief Executive Officer
and President of U.S. Bioscience, Inc., a biotechnology company. Mr. Clarke
served as President and Chief Operating Officer of U.S. Bioscience from 1996 to
1998. From 1977 to 1996, Mr. Clarke held a number of positions at Merck & Co.,
Inc., including being the first president of Pasteur-Merieux MSD, and most
recently as Vice President of Merck Vaccines. Mr. Clarke has a B.S. in
Biochemistry and an M.A. in History from the University of Calgary.
Edward J. Arcuri, Ph.D., has been our Senior Vice President, Operations
since May 2000. He joined Aviron as Vice President, Manufacturing in July 1999.
Dr. Arcuri joined us from North American Vaccine, Inc., or NAVA, where he served
as Vice President, Manufacturing Operations and Process Development from January
1995 to July 1999. Prior to joining NAVA, Dr. Arcuri served as Senior Director,
Biological Manufacturing at Merck & Co., Inc. from 1991 to 1994. Dr. Arcuri
holds a B.S. degree in Biology from the State University of New York at Albany
and a masters degree and Ph.D. in Biology from Rensselaer Polytechnic Institute.
Charlene A. Friedman has been our Vice President, General Counsel and
Secretary since April 2000. From 1999 until joining us, Ms. Friedman was a
consultant to Inamed Corporation, a medical device company. From 1996 to 1999,
Ms. Friedman held various positions at Collagen Aesthetics, Inc., a
biotechnology company, most recently as Vice President, Legal and Regulatory
Affairs, General Counsel and Assistant Secretary. From 1995 to 1996, Ms.
Friedman was an attorney with Lillick & Charles in San Francisco, California.
From 1993 to 1995, she practiced law in Boston, Massachusetts at Warner &
Stackpole. She is a member of the Massachusetts and California bars. Ms.
Friedman holds a B.A. in Ancient Greek and Latin from Tufts University and a
J.D. from Northeastern University.
Harry B. Greenberg, M.D., has been our Senior Vice President, Research and
Development and Chief Scientific Officer since November 2000. Dr. Greenberg
joined us from the Stanford University School of Medicine, where he spent 17
years as a faculty member. He was most recently the Senior Associate Dean for
Research and the Joseph D. Grant Endowed Professor of Medicine. He also was
serving as Associate Chief of Staff for Research at the Veterans Administration
Palo Alto Health Care System. Dr. Greenberg served as chair of the Vaccines and
Related Biological Products Advisory Committee of the U.S. Food and Drug
Administration from February 1999 until beginning his position with Aviron. Dr.
Greenberg holds a B.A. in History with honors from Dartmouth College and an M.D.
from Columbia College of Physicians and Surgeons.                    41
42
Fred Kurland has been our Senior Vice President and Chief Financial Officer
since January 1998. Prior to joining us, Mr. Kurland was Vice President and
Chief Financial Officer of Protein Design Labs, Inc., a biotechnology company,
from 1996 to 1998. From 1995 to 1996, Mr. Kurland was Vice President and Chief
Financial Officer at Applied Immune Sciences, a biotechnology company, and from
1981 to 1995, he held a number of positions at Syntex Corporation, a
pharmaceutical company, most recently as Vice President and Controller. Mr.
Kurland, a Certified Public Accountant, holds a B.S. in Business and Economics
from Lehigh University, and an M.B.A. and a J.D. from the University of Chicago.
Carol A. Olson has been our Senior Vice President, Commercial Development
since May 1998. Prior to joining us, Ms. Olson was the founder and managing
director of the Churchill Madison Group, a management consulting firm focused on
building new businesses in the medical, life sciences and high technology
industries. From 1984 to 1993, Ms. Olson worked for the Hewlett Packard Company.
Ms. Olson holds a B.A. in Economics with honors from Yale University and an
M.B.A. from Stanford University.
Rayasam S. Prasad has been our Senior Vice President, Technical Affairs
since January 2001 and prior to that had been our Vice President, Technical
Affairs since September 1999. Mr. Prasad joined Aviron from Chiron Vaccines, the
global vaccines business unit of Chiron Corporation, a biotechnology company,
where he served as Head of Regulatory, Quality and Drug Safety. Mr. Prasad also
served as Director of Quality Assurance for Therapeutics and Vaccines at Chiron.
He was with Chiron from October 1994 to September 1999. Prior to joining Chiron,
Mr. Prasad held positions in quality assurance and biological manufacturing
operations at Genentech, Inc. from 1986 to 1994, and Burroughs Wellcome Co. from
1981 to 1986. Mr. Prasad holds a B.S. in Pharmacy from
